Angiotech completes enrollment for Bio-Seal trial

The primary endpoint of the Bio-Seal study is a reduction in the incidence of pneumothorax in patients undergoing lung biopsy procedures when compared with patients who do not receive the Bio-Seal product. The product has already received CE Mark approval and is available for commercial sale in the EU.

Bio-Seal is a novel technology designed to reduce the incidence of post-operative pneumothorax (collapsed lung) in patients who undergo lung biopsy procedures.

William Hunter, president and CEO of Angiotech, said: “Our proprietary Bio-Seal product represents a potentially significant improvement in the technology used to diagnose lung cancer. We look forward to a review of the clinical trial data and are hopeful that the data will demonstrate a considerable reduction in the side effects related to lung biopsy procedures.”